论文部分内容阅读
目的观察基因重组人粒细胞集落刺激因子对急性白血病和恶性淋巴瘤化疗后中性粒细胞减少的治疗效果及毒副作用。方法采用随机双盲自身对照法，研究ＡＬ２１例和ＮＨＬ１３例共３４例５５个疗程次。在联合化疗４８ｈ后使用格拉诺赛特１００μｇ／ｄ×１４ｄ预防ＡＮＣ减少／缺乏并促进其恢复。结果ＡＮＬＬ和ＮＨＬ给药周期比对照组ＡＮＣ减少／缺乏的时期均明显缩短（ＡＮＣ减少期分别由２１．３ｄ和１５．４ｄ缩短到１０．５ｄ和８．２ｄ，ＡＮＣ缺乏由１１．９ｄ和７．８ｄ缩短到６．３ｄ和４．５ｄ），给药周期的感染率和发热期也短于对照周期。格拉诺赛特的毒副作用发生率是５／５５（１０％），未发现促进ＡＮＬＬ恶性细胞增殖现象，３４例５５个疗程次均耐受了全部治疗过程。结论ｒｈＧ－ＣＳＦ及其类似的造血刺激因子可刺激造血干细胞及粒细胞的分化和增殖，促进中性粒细胞的释放和提高细胞的吞噬功能，这有助于ＡＮＬＬ和ＮＨＬ强烈联合化疗后粒细胞减少／缺乏的预防，促进ＰＭＮｓ的恢复
Objective To observe the therapeutic effect and toxic side effects of recombinant human granulocyte colony-stimulating factor on neutropenia after chemotherapy in acute leukemia and malignant lymphoma. Methods A randomized, double-blind, self-analysis method was used to study the treatment of AL21 cases and NHL13 cases (34 cases, 55 cycles). Use of Granolsed 100 μg/d×14d after 48 h of combination chemotherapy prevents ANC reduction/lack and promotes its recovery. Results The period of ANLL and NHL administration was significantly shorter than that of the control group. The reduction period of ANC was shortened from 21.3d and 15.4d to 10.5d and 8.2d, and the ANC deficiency was from 11.9d and 7 respectively. .8d was shortened to 6.3d and 4.5d), and the infection rate and febrile period of the dosing period were also shorter than the control period. The incidence of side effects of Granolette is 5/55 (10%) and no evidence of proliferation of ANLL malignant cells has been found. 34 of the 55 treatments were tolerated during the entire course of treatment. Conclusion rhG-CSF and its similar hematopoietic stimulating factor can stimulate the differentiation and proliferation of hematopoietic stem cells and granulocytes, promote the release of neutrophils and increase the phagocytosis of cells, which contributes to the strong combination of ANLL and NHL after chemotherapy in granulocytes. Reduction/lack of prevention, promotion of recovery of PMNs